Evidence map›Paper›PMID 24518265›Full record

ArticleBehavioural pharmacology2014

Behavioral effects of the imidazoline I(2) receptor ligand BU99006 in rats.

Yanyan Qiu, David A Thorn, Yanan Zhang, Xiaohua He, Jun-Xu Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Behavioural pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Imidazoline IPharmacology & therapeutics · 2017
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yanyan QiuaDepartment of Physiology, School of Basic Medical Sciences, Wuhan University, Hubei, People's Republic of China bDepartment of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York cResearch Triangle Institute, Research Triangle Park, North Carolina, USA.
David A Thorn
Yanan Zhang
Xiaohua He
Jun-Xu Li
University at Buffalo, State University of New York · USRTI International · USWuhan University · CN

Funding

IMIDAZOLINE I2 RECEPTORS AS TARGETS FOR THE TREATMENT OF PAINR01DA034806 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LI, JUN-XU · 2013 to 2017
$1.7M
Orexin-1 Receptor Ligands for Drug AddictionR33DA032837 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZHANG, YANAN · 2014 to 2015
$992k
Orexin-1 Receptor Ligands for Drug AddictionR21DA032837 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZHANG, YANAN · 2012 to 2013
$519k
Behavioral effects of methamphetamine & imidazoline I2 receptor ligandsR21DA033426 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LI, JUN-XU · 2013 to 2014
$464k
NIDA NIH HHS R01 DA034806NIDA NIH HHS R01DA034806NIDA NIH HHS R21 DA032837NIDA NIH HHS R21DA032837NIDA NIH HHS R21 DA033426NIDA NIH HHS R21DA033426NIDA NIH HHS R33 DA032837
6 · The paper itself

Abstract

The imidazoline I2 receptor ligand BU99006 binds to and attenuates effects mediated by I2 receptors in vitro, although its effects in vivo have not been studied previously. This study examined the effects of BU99006 in two behavioral assays in rats: hypothermia and 2-BFI discrimination. BU99006 (3.2-15 mg/kg, intraperitoneally) produced a dose-dependent hypothermic effect (rectal temperature), which was antagonized by the I2 receptor antagonist idazoxan. BU99006 (3.2 or 10 mg/kg administered 10 min or 2 h before the session, respectively) did not significantly alter hypothermia produced by the I2 receptor agonist 2-BFI (10 mg/kg). In rats discriminating 5.6 mg/kg 2-BFI, BU99006 (1.78-17.8 mg/kg, intraperitoneally) produced 40 and 82% responding on the 2-BFI-associated lever when it was administered immediately or 2 h before the test sessions, respectively. BU99006 enhanced the discriminative stimulus and rate-suppressing effects of 2-BFI. Collectively, these data suggest that BU99006 is an imidazoline I2 receptor agonist with no evidence of I2 receptor antagonism in rats.

Indexed as

AnimalsBenzofuransBody TemperatureCentral Nervous System AgentsDiscrimination, PsychologicalDose-Response Relationship, DrugHypothermiaIdazoxanImidazolesImidazoline ReceptorsMaleRatsRats, Sprague-Dawley2-(2-benzofuranyl)-2-imidazolineBenzofuransBU 99006Central Nervous System AgentsIdazoxanImidazolesImidazoline Receptors

Identifiers

PMID24518265
PMCPMC4180046
OpenAlexW2012676605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.